Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen-reduced platelets

British Journal of Haematology

Volumn 188, Issue 3, 2020, Pages 465-472

  Bahar, Burak ^a   Schulz, Wade L ^a,b   Gokhale, Amit ^a   Spencer, Bryan R ^c   Gehrie, Eric A ^d   Snyder, Edward L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c AMERICAN RED CROSS   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

efficacy; pathogen reduction; platelets; transfusion; transfusion reaction

Indexed keywords

ADULT; ARTICLE; BLOOD TRANSFUSION REACTION; CLINICAL EFFECTIVENESS; CONNECTICUT; CONTROLLED STUDY; ERYTHROCYTE COUNT; ERYTHROCYTE TRANSFUSION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOGEN REDUCED PLATELET; PLATELET COUNT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SEPTIC TRANSFUSION REACTION; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TIME TO TREATMENT; ADVERSE EVENT; DISINFECTION; MIDDLE AGED;

ADULT; BLOOD PLATELETS; DISINFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; TRANSFUSION REACTION;

EID: 85073994409     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.16187     Document Type: Article

References (37)

1. Arefian, H., Heublein, S., Scherag, A., Brunkhorst, F.M., Younis, M.Z., Moerer, O., Fischer, D. & Hartmann, M. (2017) Hospital-related cost of sepsis: a systematic review. Journal of Infection, 74, 107–117.
2. Benjamin, R.J., McDonald, C.P.; ISBT Transfusion Transmitted Infectious Disease Bacterial Workgroup. (2014) The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines. Transfusion Medicine Reviews, 28, 61–71.
3. Benjamin, R.J., Braschler, T., Weingand, T. & Corash, L.M. (2017) Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems. Transfusion, 57, 2946–2957.
4. Bihl, F., Castelli, D., Marincola, F., Dodd, R.Y. & Brander, C. (2007) Transfusion-transmitted infections. Journal of Translational Medicine, 5, 25.
5. Burnouf, T. & Radosevich, M. (2000) Reducing the risk of infection from plasma products: specific preventative strategies. Blood Reviews, 14, 94–110.
6. Cazenave, J.P., Follea, G., Bardiaux, L., Boiron, J.M., Lafeuillade, B., Debost, M., Lioure, B., Harousseau, J.L., Tabrizi, R., Cahn, J.Y. & Michallet, M. (2010) A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion, 50, 2362–2375.
7. CDC (2018) National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol. v2.5.2. Centers for Disease Control and Prevention, Atlanta, GA. Available at: http://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf. (Accessed 18 September 2018).
8. Ellingson, K.D., Sapiano, M.R.P., Haass, K.A., Savinkina, A.A., Baker, M.L., Chung, K.W., Henry, R.A., Berger, J.J., Kuehnert, M.J. & Basavaraju, S.V. (2017) Continued decline in blood collection and transfusion in the United States-2015. Transfusion, 57, 1588–1598.
9. Estcourt, L.J., Malouf, R., Hopewell, S., Trivella, M., Doree, C., Stanworth, S.J. & Murphy, M.F. (2017) Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Systematic Review, 7, CD009072.
10. FAMHP (2016) Annual Hemovigilance Annual Reports 2006–2015. Federal Agency for Medicines and Health Product. Available at: https://www.famhp.be/en/human_use/health_products/blood_and_blood_products/haemovigilance/annual_reports. (Accessed Jun 21, 2019).
11. FDA (2017) Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for FY2017. US Food and Drug Administration. Available at: https://www.fda.gov/media/124796/download. (Accessed 24 May 2019).
12. FDA (2018) Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion. FDA, Available at: https://www.fda.gov/media/119043/download. (Accessed 24 May 2019).
13. Garban, F., Guyard, A., Labussiere, H., Bulabois, C.E., Marchand, T., Mounier, C., Caillot, D., Bay, J.O., Coiteux, V., Schmidt-Tanguy, A., Le Niger, C., Robin, C., Ladaique, P., Lapusan, S., Deconinck, E., Rolland, C., Foote, A.M., Francois, A., Jacquot, C., Tardivel, R., Tiberghien, P. & Bosson, J.L.; Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process Study Group. (2018) Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial. JAMA Oncology, 4, 468–475.
14. Haass, K.A., Sapiano, M.R., Savinkina, A., Kuehnert, M.J. & Basavaraju, S.V. (2019) Transfusion-transmitted infections reported to the national healthcare safety network hemovigilance module. Transfusion Medicine Reviews, 33, 84–91.
15. Jacobs, M.R., Smith, D., Heaton, W.A., Zantek, N.D. & Good, C.E.; PGD Study Group. (2011) Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion, 51, 2573–2582.
16. Jenkins, C., Ramirez-Arcos, S., Goldman, M. & Devine, D.V. (2011) Bacterial contamination in platelets: incremental improvements drive down but do not eliminate risk. Transfusion, 51, 2555–2565.
17. Jones, S.A. (2019) Sepsis attributed to bacterial contamination of platelets associated with a potential common source—multiple states, 2018. MMWR. Morbidity and Mortality Weekly Report, 68, 519–523.
18. Jutzi, M., Mansouri Taleghani, B., Rueesch, M., Amsler, L. & Buser, A. (2018) Nationwide implementation of pathogen inactivation for all platelet concentrates in Switzerland. Transfusion Medicine and Hemotherapy, 45, 151–156.
19. Kacker, S., Bloch, E.M., Ness, P.M., Gehrie, E.A., Marshall, C.E., Lokhandwala, P.M. & Tobian, A.A.R. (2019) Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions. Transfusion, 59, 1291–1299.
20. Kerkhoffs, J.L., van Putten, W.L., Novotny, V.M., Te Boekhorst, P.A., Schipperus, M.R., Zwaginga, J.J., van Pampus, L.C., de Greef, G.E., Luten, M., Huijgens, P.C., Brand, A., van Rhenen, D.J.; Dutch - Belgian HOVON Cooperative Group. (2010) Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. British Journal of Haematology, 150, 209–217.
21. Klein, H.G., Anderson, D., Bernardi, M.J., Cable, R., Carey, W., Hoch, J.S., Robitaille, N., Sivilotti, M.L. & Smaill, F. (2007) Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion, 47, 2338–2347.
22. Knutson, F., Osselaer, J., Pierelli, L., Lozano, M., Cid, J., Tardivel, R., Garraud, O., Hervig, T., Domanovic, D., Cukjati, M., Gudmundson, S., Hjalmarsdottir, I.B., Castrillo, A., Gonzalez, R., Brihante, D., Santos, M., Schlenke, P., Elliott, A., Lin, J.S., Tappe, D., Stassinopoulos, A., Green, J. & Corash, L. (2015) A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sanguinis, 109, 343–352.
23. Larsen, C.P., Ezligini, F., Hermansen, N.O. & Kjeldsen-Kragh, J. (2005) Six years' experience of using the BacT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false-negative results. Vox Sanguinis, 88, 93–97.
24. Lozano, M., Knutson, F., Tardivel, R., Cid, J., Maymo, R.M., Lof, H., Roddie, H., Pelly, J., Docherty, A., Sherman, C., Lin, L., Propst, M., Corash, L. & Prowse, C. (2011) A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. British Journal of Haematology, 153, 393–401.
25. Lozano, M., Cid, J., Prowse, C., McCullough, J., Klein, H.G. & Aubuchon, J.P. (2015) Pathogen inactivation or pathogen reduction: proposal for standardization of nomenclature. Transfusion, 55, 690.
26. McCullough, J., Vesole, D.H., Benjamin, R.J., Slichter, S.J., Pineda, A., Snyder, E., Stadtmauer, E.A., Lopez-Plaza, I., Coutre, S., Strauss, R.G., Goodnough, L.T., Fridey, J.L., Raife, T., Cable, R., Murphy, S., Howard, F.T., Davis, K., Lin, J.S., Metzel, P., Corash, L., Koutsoukos, A., Lin, L., Buchholz, D.H. & Conlan, M.G. (2004) Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood, 104, 1534–1541.
27. McCullough, J., Goldfinger, D., Gorlin, J., Riley, W.J., Sandhu, H., Stowell, C., Ward, D., Clay, M., Pulkrabek, S., Chrebtow, V. & Stassinopoulos, A. (2015) Cost implications of implementation of pathogen-inactivated platelets. Transfusion, 55, 2312–2320.
28. McPadden, J., Durant, T.J., Bunch, D.R., Coppi, A., Price, N., Rodgerson, K., Torre, C.J. Jr, Byron, W., Hsiao, A.L., Krumholz, H.M. & Schulz, W.L. (2019) Health care and precision medicine research: analysis of a scalable data science platform. Journal of Medical Internet Research 21, e13043.
29. Prioli, K.M., Karp, J.K., Lyons, N.M., Chrebtow, V., Herman, J.H. & Pizzi, L.T. (2018) Economic implications of pathogen reduced and bacterially tested platelet components: a US hospital budget impact model. Applied Health Economics and Health Policy, 16, 889–899.
30. Rebulla, P., Vaglio, S., Beccaria, F., Bonfichi, M., Carella, A., Chiurazzi, F., Coluzzi, S., Cortelezzi, A., Gandini, G., Girelli, G., Graf, M., Isernia, P., Marano, G., Marconi, M., Montemezzi, R., Olivero, B., Rinaldi, M., Salvaneschi, L., Scarpato, N., Strada, P., Milani, S. & Grazzini, G. (2017) Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion, 57, 1171–1183.
31. van Rhenen, D., Gulliksson, H., Cazenave, J.P., Pamphilon, D., Ljungman, P., Kluter, H., Vermeij, H., Kappers-Klunne, M., de Greef, G., Laforet, M., Lioure, B., Davis, K., Marblie, S., Mayaudon, V., Flament, J., Conlan, M., Lin, L., Metzel, P., Buchholz, D. & Corash, L. (2003) Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood, 101, 2426–2433.
32. Rutter, S. & Snyder, E.L. (2019) How do we … integrate pathogen reduced platelets into our hospital blood bank inventory? Transfusion, 59, 1628–1636.
33. Salunkhe, V., van der Meer, P.F., de Korte, D., Seghatchian, J. & Gutierrez, L. (2015) Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfusion and Apheresis Science, 52, 19–34.
34. Schulz, W.L., McPadden, J., Gehrie, E.A., Bahar, B., Gokhale, A., Ross, R., Price, N., Spencer, B.R. & Snyder, E. (2019) Blood utilization and transfusion reactions in pediatric patients transfused with conventional or pathogen reduced platelets. The Journal of Pediatrics, 209, 220–225.
35. Seltsam, A. (2017) Pathogen inactivation of cellular blood products-an additional safety layer in transfusion medicine. Frontiers in Medicine 4, 219.
36. SHOT. (2019) Serious Hazards of Transfusion annual reports and summaries 1996–2017. Available at: https://www.shotuk.org/shot-reports/. (Accessed 20 June 2019).
37. WHO. (2017) Global Status Report on Blood Safety and Availability 2016. World Health Organization. Available at: https://apps.who.int/iris/handle/10665/254987. (Accessed 27 February 2017).